Article Text

PDF
Remission of the clinical signs of atopic dermatitis in dogs after cessation of treatment with cyclosporin A or methyiprednisolone
  1. J. Steffan, MS,
  2. J. Horn, DVM, PhD, MRCVS,
  3. P. Gruet, DVM,
  4. G. Strehlau, PhD1,
  5. A. Fondati, DVM,
  6. L. Ferrer, DVM, PhD2 and
  7. C. Noli, DVM, DipECVD3
  1. 1 Novartis Animal Health, CH-4002 Basel, Switzerland
  2. 2 Facultad de Veterinaria, Universidad Autonoma de Barcelona, 08193 Bellaterra (Barcelona), Spain
  3. 3 Strada Madonna 58, 12016 Peveragno (CN), Italy

Abstract

Seventy-eight dogs with atopic dermatitis were treated for four months with either cyclosporin A or methylprednisolone. During the two months after the treatment ceased, 87 per cent of the dogs treated with methylprednisolone relapsed after a mean period of 27.9 days, whereas only 62 per cent of the dogs treated with cyclosporin A relapsed after a mean period of 40.7 days (P<0.001). The clinical condition of the dogs was evaluated either when they relapsed, or two months after the treatment ceased if they had not relapsed. Both the skin lesions and pruritus increased significantly more markedly in the dogs treated with methylprednisolone than in those treated with cyclosporin A. At the end of the study the skin lesions were markedly less severe than before the therapy; in the dogs in both groups that did not relapse, the lesion score was improved by 77 per cent two months after the treatment had stopped, and in the dogs that did relapse the lesion scores had improved by 45 per cent and 35 per cent in the dogs treated with cyclosporin A and methylprednisolone, respectively. Pruritus remained well controlled in the dogs that did not relapse, but increased to baseline levels or close to baseline in the dogs that relapsed.

    Statistics from Altmetric.com

      Request permissions

      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.